October 19, 2012 12:45 ET

Free Reports on Aegerion, CytRx, Chimera and Boston Scientific Provided by the Bedford Report

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the CAPITAL NEWS CIRCUIT.

NEW YORK, NY--(Marketwire - Oct 19, 2012) - The Bedford Report has released new equity reports today. As a leading provider of free in-depth reports and timely market updates, Bedford has been an essential resource for hundreds of thousands of investors across the country.

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) shares surged nearly 10 percent after it was reported the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended approval of lomitapid for the treatment of Homozygous Familial Hypercholesterolemia.

Find out more about Aegerion Pharmaceuticals including full access to the free equity report at:

CytRx Corporation (NASDAQ: CYTR) declined nearly 20 percent Thursday after announcing the pricing of a public offering of 8 million shares of common stock. The company recently initiated a single-center Phase 1b clinical trial for aldoxorubicin in the treatment of metastatic solid tumors.

Find out more about CytRx including full access to the free equity report at:

Chimera Investment Corporation (NYSE: CIM) shares have rebounded over 15 percent in the last three months. The company has benefited from recent measure that will keep interest rates near zero till at least mid-2015.

Find out more about Chimera including full access to the free equity report at:

Boston Scientific Corporation (NYSE: BSX) shares declined 4 percent on 3 times the average daily volume after the company reported a third quarter 2012 net loss of $725 million, compared to a profit of $142 million in the year-ago quarter, due mostly to a $809 million write-down of the company's cardiac division.

Find out more about Boston Scientific including full access to the free equity report at:

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid Capital News Circuit one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Certain information included may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. We accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

Contact Information